Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
作者信息
Fröhlich Karen, Holle Julia U, Aries Peer M, Gross Wolfgang L, Moosig Frank
出版信息
Ann Rheum Dis. 2011 Jul;70(7):1344-5. doi: 10.1136/ard.2010.133256. Epub 2010 Dec 20.
PMID:21173019
Abstract
摘要
相似文献
1
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.硼替佐米成功用于一名系统性红斑狼疮合并多发性骨髓瘤患者。
Ann Rheum Dis. 2011 Jul;70(7):1344-5. doi: 10.1136/ard.2010.133256. Epub 2010 Dec 20.
2
Bortezomib for myeloma -- much ado about something.硼替佐米治疗骨髓瘤——小题大做。
N Engl J Med. 2005 Jun 16;352(24):2546-8. doi: 10.1056/NEJMe058059.
3
Lenalidomide for bortezomib-resistant multiple myeloma.来那度胺用于硼替佐米耐药的多发性骨髓瘤。
Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c1; author reply doi:10.1038/nrclinonc.2010.31-c3.
4
Lenalidomide efficacy in bortezomib-resistant myeloma.来那度胺在硼替佐米耐药性骨髓瘤中的疗效。
Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c2; author reply doi:10.1038/nrclinonc.2010.31-c3.
5
First proteasome inhibitor approved for multiple myeloma.首个获批用于治疗多发性骨髓瘤的蛋白酶体抑制剂。
J Natl Cancer Inst. 2003 Jun 18;95(12):845. doi: 10.1093/jnci/95.12.845.
6
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.在一例对硼替佐米产生临床耐药的骨髓瘤病例中，未发现蛋白酶体β5亚基（PSMB5）发生突变的证据。
Leuk Res. 2006 Feb;30(2):240-1. doi: 10.1016/j.leukres.2005.06.014. Epub 2005 Aug 2.
7
Diagnosis and the current trends in multiple myeloma therapy.多发性骨髓瘤的诊断与当前治疗趋势
Pol Arch Med Wewn. 2008 Oct;118(10):563-6.
8
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.硼替佐米：多发性骨髓瘤髓外疾病的有效药物。
Eur J Haematol. 2006 May;76(5):405-8. doi: 10.1111/j.0902-4441.2005.t01-1-EJH2462.x. Epub 2006 Mar 9.
9
Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
Acta Haematol. 2005;114(3):170-3. doi: 10.1159/000087894.
10
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
Leuk Lymphoma. 2009 Jun;50(6):1033-5. doi: 10.1080/10428190902919218.
引用本文的文献
1
Clinical advances in immunotherapy for immune-mediated glomerular diseases.免疫介导性肾小球疾病免疫治疗的临床进展。
Clin Exp Med. 2023 Dec;23(8):4091-4105. doi: 10.1007/s10238-023-01218-7. Epub 2023 Oct 27.
2
Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases.硼替佐米治疗伴有精神病性症状的严重儿童起病神经精神性系统性红斑狼疮有效：病例系列及抗体介导性疾病中 B 细胞免疫调节的小型综述
Clin Rheumatol. 2023 Jul;42(7):1965-1979. doi: 10.1007/s10067-023-06559-y. Epub 2023 Mar 27.
3
Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors.选择性免疫蛋白酶体抑制剂的发现和早期临床开发。
Cells. 2021 Dec 21;11(1):9. doi: 10.3390/cells11010009.
4
Bortezomib in autoimmune hemolytic anemia and beyond.硼替佐米在自身免疫性溶血性贫血及其他病症中的应用
Ther Adv Hematol. 2021 Nov 12;12:20406207211046428. doi: 10.1177/20406207211046428. eCollection 2021.
5
Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis.血清20S蛋白酶体水平与髓过氧化物酶-抗中性粒细胞胞浆抗体相关性显微镜下多血管炎的疾病活动相关。
BMC Rheumatol. 2020 Aug 25;4:36. doi: 10.1186/s41927-020-00137-4. eCollection 2020.
6
New Trials in Lupus and where Are we Going.狼疮新试验及未来走向
Curr Rheumatol Rep. 2018 May 3;20(6):34. doi: 10.1007/s11926-018-0745-1.
7
Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.硼替佐米治疗在疾病活动度较高的狼疮模型小鼠中诱导出更高的死亡率。
Arthritis Res Ther. 2017 Aug 11;19(1):187. doi: 10.1186/s13075-017-1397-7.
8
Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.免疫蛋白酶体β5i选择性二肽模拟物抑制剂
ChemMedChem. 2016 Oct 6;11(19):2127-2131. doi: 10.1002/cmdc.201600384. Epub 2016 Aug 25.
9
Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.在硼替佐米治疗狼疮性肾炎和心肌炎危重症患者期间（免疫）蛋白酶体抑制作用的药效动力学监测。
Lupus Sci Med. 2015 Dec 18;2(1):e000121. doi: 10.1136/lupus-2015-000121. eCollection 2015.
10
Analyzing pathogenic (double-stranded (ds) DNA-specific) plasma cells via immunofluorescence microscopy.通过免疫荧光显微镜分析致病性（双链（ds）DNA特异性）浆细胞。
Arthritis Res Ther. 2015 Oct 21;17:293. doi: 10.1186/s13075-015-0811-2.
Zotero 插件